Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)3.98
  • Today's Change0.07 / 1.79%
  • Shares traded30.62k
  • 1 Year change-28.29%
  • Beta0.7600
Data delayed at least 15 minutes, as of Apr 24 2017 20:59 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Apr 21, 2017, the investment analyst covering CTI BioPharma Corp advises that the company will underperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Mar 29, 2017. The previous consensus forecast advised investors to hold their position in CTI BioPharma Corp.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy0
Outperform0
Hold0
Underperform1
Sell0

Earnings history & estimates

On Mar 02, 2017, CTI BioPharma Corp reported 4th quarter 2016 losses of -0.23 per share. This result exceeded the -0.600 consensus loss of the one analyst covering the company and under-performed last year's 4th quarter results by 82.31%.
The next earnings announcement is expected on May 08, 2017.
Average growth rate+17.07%
CTI BioPharma Corp reported annual 2016 losses of -1.86 per share on Mar 02, 2017.
Average growth rate+25.74%
More ▼

Revenue history & estimates

CTI BioPharma Corp. had 4th quarter 2016 revenues of 9.14m. This bettered the 700.00k estimate of the one analyst covering the company. This was 19.32% below the prior year's 4th quarter results.
Average growth rate+52.15%
CTI BioPharma Corp. had revenues for the full year 2016 of 57.41m. This was 256.20% above the prior year's results.
Average growth rate+893.09%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.